Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Intradermal BCG TICE Vaccination and Challenge in Healthy Volunteers
NCT06845358Phase 1Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label trial of bcg vaccine in Tuberculosis (TB) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Area under the curve for repeated measures of shedding over time from MGIT BACTEC assays, Serious adverse events and/or Medically Attended Adverse Events and 4 more. Planned start Nov 2025; status: withdrawn.
02
Drugs
bcg vaccine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06845358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06845358.